Abstract: The purpose of this study is to analyse the response of a single HEXITEC detector system when it is exposed to complex radiation fields such as proton beam therapy and evaluate its ...

designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with ...

Graham Corporation's robust balance sheet, with no debt and $30M net cash, offers financial flexibility and security within the debt-laden Russell 2000 Index. Its financial growth is among the ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease ... Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing ...